CA-THERMO-FISHER
Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments. This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer.
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for platinum-resistant ovarian cancer. ArsenalBio’s work to develop multi-functional CAR-T cell therapies is enabled by Thermo Fisher’s Cell Therapy Systems (CTS) portfolio of products, including the Gibco™ CTS™ Xenon™ Electroporation System and the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System.
“Our programmable cell therapy technology holds the potential to help patients with aggressive and complex cancers who currently have few treatment options,” said Ken Drazan, M.D., co-founder and chief executive officer, ArsenalBio. “To bring the promise of this technology to patients we’ll need to execute at speed and scale as we transition to clinical development. Our relationship with Thermo Fisher allows us to combine their fit-for-purpose solutions and internal expertise with our team’s innovative approach to clinical research and process development capabilities to manufacture ArsenalBio’s products and explore future therapeutic innovation.”
Thermo Fisher began its collaboration with ArsenalBio in 2020 to help ArsenalBio overcome challenges associated with cell therapy manufacturing by working together to support development of a clinical-scale gene editing process. In addition, ArsenalBio received early access to Thermo Fisher’s latest instrumentation and reagents.
“By collaborating with ArsenalBio as they pioneer a new approach to treat solid tumors using engineered T cell therapies, we’re helping bring more options to those who are most in need of innovative treatments,” said Betty Woo, vice president of cell, gene and advanced therapies, Thermo Fisher. “Through our Cell Therapy Collaboration Program, we are enabling the industry shift from reactive to proactive, applying our biological and technical expertise to improve the economics of therapy production, and moving toward expanded access to patients worldwide.”
Thermo Fisher’s CTS portfolio of products are cGMP manufactured, designed to meet applicable cell therapy standards, and include traceability and regulatory documentation to help customers transition from research to clinical production.
For more information about Thermo Fisher’s cell therapy collaboration partnership program, please visit thermofisher.com/collabcenterpartnership.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005043/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shin-Etsu Chemical Develops New Silicone Products for Personal Care Use That Will Improve Texture and Functionality in Cosmetics12.5.2025 08:30:00 CEST | Press release
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) has developed new silicone products for personal care applications as part of its silicon chemistry-driven solutions (Shin-Etsu Silicones Solution-EngineeringTM). In the personal care industry, research and development activities are being carried out on various themes such as addressing diverse consumer demand and environmental issues and improving production efficiency. In response to these needs, Shin-Etsu Chemical has added new products to its lineup. [New Products] KF-6070W and KF-6080W are silicones in which some of the methyl groups in the molecular structure of dimethyl silicone oil (INCI name: dimethicone) have been replaced with hydrophilic functional groups. Both products combine high affinity with water due to their hydrophilic functional groups, while also imparting the excellent characteristics of silicone—high fluidity and smooth, non-sticky feel—to cosmetics
Cooler Master Launches Hyper 612 APEX: Compact, High-Performance CPU Cooler for Modern Builds12.5.2025 08:05:00 CEST | Press release
Advanced superconductive heat pipes and streamlined design deliver elite cooling power with greater system compatibility. Cooler Master, a global leader in PC components and tech lifestyle solutions, today unveiled the Hyper 612 APEX, an all-new CPU air cooler engineered for users who demand cutting-edge thermal performance in a streamlined footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250511858017/en/ Cooler Master Hyper 612 APEX air cooler Featuring in-house developed superconductive composite heat pipes and the high-powered Mobius 120P fan, the Hyper 612 APEX delivers exceptional cooling efficiency while being 30% smaller than its predecessor, ensuring enhanced compatibility with large memory modules and tighter system builds. Ideal for gamers, content creators, and overclockers, the Hyper 612 APEX is meticulously designed to balance elite performance, user-friendly installation, and sleek aesthetics. “The Hyp
Zeon and Sino Applied Technology Join Hands to Expand Single-Walled Carbon Nanotube Conductive Paste Product Line and Promote the Application of Next-Generation Lithium Batteries in Electric Vehicles12.5.2025 08:00:00 CEST | Press release
Zeon Corporation (Zeon) and Sino Applied Technology (SiAT) are thrilled to announce the signing of a strategic partnership in Taoyuan, Taiwan. As part of this collaboration, Zeon will lead a $20 million USD Series C fundraising round in SiAT to support the expansion of its production capacity for single-walled carbon nanotube (SWCNT) conductive paste, a critical nanomaterial for next-generation battery technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250511242604/en/ ZEONANO®, Single-Walled Carbon Nanotube produced by Zeon Super Growth Method The global demand for lithium-ion batteries is surging across consumer applications—such as electric vehicles, drones, and EVTOL aircraft—as well as industrial sectors, including AI server BBUs, renewable energy ESS, and automated robotics. This growth has intensified the need for SWCNTs, which can significantly enhance battery energy density and cycle life. Unlike tradition
New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care10.5.2025 12:45:00 CEST | Press release
Data presented at ADHD World Congress highlights how QbCheck supports diagnostic accuracy and individualized treatment monitoring, enabling efficient and robust care in virtual settings. News Summary: New findings show significant improvements in access, clinician confidence, symptom tracking, and individualized care using objective testing. The study underscores the importance of scalable, evidence-based tools, as many countries, including both the UK and the US, face rising demand for ADHD diagnosis and treatment. The study revealed significant improvements post-treatment, validating clinical practice and better clinician-patient alignment. As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Pra
Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model9.5.2025 15:57:00 CEST | Press release
The Time-Series Transformer AI FX Model forecasts cashflow and FX exposure with more than 90% accuracy, helping businesses reduce FX-related fees Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities. At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays. Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts patterns over time. Ant also created new pre-training and Supervised Fine-Tuning (SFT) frameworks to train the model
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom